The Effects of Real-World Evidence on the Treatment of HER2+ mBC

Joseph Gligorov, MD, reviews advancements in the treatment of HER2-positive breast cancer, including the pivotal DESTINY-Breast03 study, global perspectives, sequencing strategies based on French real-world evidence, and the management of adverse events in advanced therapies.

EP. 1: Evolution of Advanced HER2+ Breast Cancer Management

October 13th 2023

Jane Meisel, MD, highlights how recent advancements in HER2+ advanced breast cancer treatments such as the introduction of tucatinib and trastuzumab deruxtecan are transforming patient care, particularly for those with brain metastases.

EP. 2: Current Standard of Care for HER2+ Metastatic Breast Cancer (mBC)

October 13th 2023

Jane Meisel, MD, details the current standard-of-care for HER2+ metastatic breast cancer in the US, emphasizing personalized care and the importance of shared decision-making with patients.

EP. 3: The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC

October 20th 2023

Jane Meisel, MD, elaborates on the evolution and significance of the antibody-drug conjugate trastuzumab deruxtecan in treating HER2+ metastatic breast cancer, highlighting its effectiveness and considerations for its usage.

EP. 4: Approaches to Sequencing Therapies for HER2+ mBC

October 20th 2023

Jane Meisel, MD, describes a personalized approach to later lines of treatment for HER2+ metastatic breast cancer, explaining the importance of considering patient priorities and individual circumstances.

EP. 5: Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC

October 27th 2023

Jane Meisel, MD, emphasizes the growing role of real-world evidence in guiding therapy sequencing for HER2+ metastatic breast cancer due to rapidly evolving treatment standards.

EP. 6: Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC

October 27th 2023

Jane Meisel, MD, discusses managing adverse events in patients receiving second- or third-line treatments for HER2+ metastatic breast cancer, emphasizing close monitoring, patient communication, and symptom-specific interventions.

EP. 7: Global Perspectives: Evolution of Advanced HER2+ Breast Cancer Treatment

November 2nd 2023

Joseph Gligorov, MD, reviews advances in the treatment of advanced HER2+ breast cancer, shares his global perspective, and explains how ESMO and NCCN guidelines are similar.

EP. 8: Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)

November 2nd 2023

Dr Joseph Gligorov highlights the impact of trastuzumab deruxtecan in treating HER2-positive breast cancer due to its impressive results in progression-free survival and overall survival, emphasizing its importance in early treatment, while acknowledging the need to monitor safety issues.

EP. 9: Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan

November 3rd 2023

Jane Meisel, MD, delves into considerations around discontinuing trastuzumab deruxtecan for the treatment of HER2+ metastatic breast cancer, explaining that therapy may be halted due to disease progression or toxicity, and the importance of monitoring patients with regular scans.

EP. 10: Novel Therapies Under Investigation for HER2+ mBC

November 3rd 2023

Jane Meisel, MD, shares enthusiasm about upcoming trials and therapies in HER2+ metastatic breast cancer, with new antibody-drug conjugates showing promise.